sericic acid: RN refers to (2alpha,3beta,4beta,19alpha)-isomer; from Vochysia divergens
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Vochysia divergens | species | [no description available] | Vochysiaceae | [no description available] |
ID Source | ID |
---|---|
PubMed CID | 124214 |
CHEMBL ID | 1078651 |
SCHEMBL ID | 5799851 |
MeSH ID | M0255378 |
Synonym |
---|
sericic acid |
(1s,4ar,6ar,6as,6br,8ar,9s,10r,11r,12ar,14bs)-1,10,11-trihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid |
55306-03-1 |
CHEMBL1078651 |
(2alpha,3beta,4beta,19alpha)-2,3,19,23-tetrahydroxyolean-12-en-28-oic acid |
2,3,19,23-tetrahydroxyolean-12-en-28-oic acid |
olean-12-en-28-oic acid, 2,3,19,23-tetrahydroxy-, (2alpha,3beta,4beta,19alpha)- |
SCHEMBL5799851 |
HB4081 |
sericic acid, >=95% (lc/ms-elsd) |
DTXSID40970632 |
AKOS040763084 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID471380 | Inhibition of yeast alpha-glucosidase after 15 mins | 2009 | Journal of natural products, Oct, Volume: 72, Issue:10 | Triterpenoid saponins from Rubus ellipticus var. obcordatus. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (67.69) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |